Working… Menu

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01186991
Recruitment Status : Completed
First Posted : August 23, 2010
Last Update Posted : January 20, 2017
Hoffmann-La Roche
Information provided by (Responsible Party):
Genentech, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016
Certification/Extension First Submitted : July 15, 2016